Precision Biosciences Inc
DTIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357874
No open-market purchases or sales by Precision Biosciences Inc insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $138.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Precision Biosciences Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Precision Biosciences Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Germano Geno J | Director | 44,883 | Jun 5, 2026 | 3 |
| Brown Melinda | Director | 44,346 | Jun 5, 2026 | 3 |
| Buehler Kevin | Director | 49,137 | Jun 5, 2026 | 2 |
| Frankel Stanley | Director | 40,478 | Jun 5, 2026 | 4 |
| Pire Shari Lisa | Director | 35,028 | Jun 5, 2026 | 2 |
| Kelly John Alexander | Chief Financial Officer | 125,883 | Jun 3, 2026 | 4 |
| Smith J. Jefferson | Chief Research Officer | 121,926 | Jun 3, 2026 | 3 |
| Scimeca Dario | General Counsel and Secretary | 56,457 | Jun 3, 2026 | 4 |
| Amoroso Michael | President and CEO | 243,392 | Jun 3, 2026 | 4 |
| Wadsworth Samuel C. | Director | 4,202 | Jun 6, 2024 | 0 |
| List Alan | Chief Medical Officer | 4,488 | May 3, 2024 | 0 |
| Barton Shane | VP & Corporate Controller | 27,502 | Jun 9, 2023 | 0 |
| Jantz Derek | Chief Scientific Officer | 4,055,174 | Jun 9, 2022 | 0 |
| Schinazi Raymond F | Director | – | May 12, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2025 (view filing) | Nov 3 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −665 | $6.49 | −$4.32K | −2.3%28.3K after | 10b5-1 |
| Nov 4, 2025 (view filing) | Nov 3 | 1 day | Kelly John AlexanderChief Financial Officer | SSale | −1.30K | $6.49 | −$8.46K | −1.7%77.3K after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Brown MelindaDirector | PPurchase | +1.38K | $4.97 | +$6.86K | +6.3%23.3K after | |
| Dec 17, 2025 (view filing) | Dec 16 | 1 day | Frankel StanleyDirector | PPurchase | +2.70K | $4.70 | +$12.7K | +16.1%19.5K after | |
| Dec 17, 2025 (view filing) | Dec 16 | 1 day | Germano Geno JDirector | PPurchase | +3.00K | $4.72 | +$14.2K | +14.4%23.9K after | |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Smith J. JeffersonChief Research Officer | SSale | −10.2K | $4.03 | −$41.1K | −8.5%110.2K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Kelly John AlexanderChief Financial Officer | SSale | −15.2K | $4.03 | −$61.3K | −12.5%106.4K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −8.85K | $4.03 | −$35.7K | −16.5%44.7K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 22 | Same day | Amoroso MichaelPresident and CEO | SSale | −34.8K | $4.17 | −$145.1K | −15.1%196.2K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Smith J. JeffersonChief Research Officer | SSale | −4.92K | $3.84 | −$18.9K | −3.9%121.9K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −4.92K | $3.84 | −$18.9K | −8.0%56.5K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Kelly John AlexanderChief Financial Officer | SSale | −8.15K | $3.84 | −$31.3K | −6.1%125.9K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Amoroso MichaelPresident and CEO | SSale | −20.6K | $3.84 | −$78.9K | −7.8%243.4K after | 10b5-1 |